本页面由Tiger Trade Technology Pte. Ltd.提供服务

Akari Therapeutics PLC

5.12
+0.510011.06%
盘后4.83-0.2853-5.57%19:59 EDT
成交量:1.31万
成交额:6.47万
市值:586.00万
市盈率:-0.25
高:5.27
开:4.61
低:4.61
收:4.61
52周最高:63.20
52周最低:3.25
股本:114.45万
流通股本:86.33万
量比:1.09
换手率:1.52%
股息:- -
股息率:- -
每股收益(TTM):-20.5537
每股收益(LYR):-20.5537
净资产收益率:-68.43%
总资产收益率:-15.36%
市净率:0.21
市盈率(LYR):-0.25

数据加载中...

2022/11/04

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2022/10/12

招股说明书

F-1 - Registration statement for certain foreign private issuers
2022/05/16

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/14

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/08/30

SEC问询函

CORRESP [Cover] - Correspondence
2021/04/21

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/12/30

SEC问询函

CORRESP [Cover] - Correspondence
2020/11/16

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/08/11

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/24

SEC问询函

CORRESP [Cover] - Correspondence
2020/07/17

招股说明书

F-1 - Registration statement for certain foreign private issuers
2020/07/02

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/04/15

SEC问询函

CORRESP [Cover] - Correspondence
2020/03/31

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/03/31

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/30

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2020/03/04

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/20

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]